ID

33086

Description

Pioglitazone Versus Metformin in Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00815399

Lien

https://clinicaltrials.gov/show/NCT00815399

Mots-clés

Versions (1)
  1. 26/11/2018 26/11/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

26 novembre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Type 2 Diabetes NCT00815399

Anglais

Eligibility Type 2 Diabetes NCT00815399

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
men and women aged 30-75 years, with newly-diagnosed type 2 diabetes (according to the ada criteria) and never treated with antihyperglycemic drugs, were selected for the study. inclusion criteria also included a body mass index (bmi) >25 kg/m2, and hba1c level <10%.
Description

Age | Diabetes Mellitus, Non-Insulin-Dependent | Hypoglycemic Agents Absent | Body mass index | Hemoglobin A1c measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0011860
UMLS CUI [3,1]
C0020616
UMLS CUI [3,2]
C0332197
UMLS CUI [4]
C1305855
UMLS CUI [5]
C0474680
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnancy or breast-feeding
Description

Pregnancy | Breast Feeding

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
any investigational drug within the previous 3 months
Description

Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1]
C0013230
use of agents affecting glycemic control (systemic glucocorticoids, and weight-loss drugs)
Description

Pharmaceutical Preparations Affecting Glycaemia control | Glucocorticoids, Systemic | Weight-Loss Agents

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C3267174
UMLS CUI [2]
C3540777
UMLS CUI [3]
C0376606
presence of any clinically relevant somatic or mental diseases that anticipated poor adherence to diet regimens
Description

Disease Somatic | Mental disorders | Adherence Poor Diet therapy

Type de données

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C2986476
UMLS CUI [2]
C0004936
UMLS CUI [3,1]
C1510802
UMLS CUI [3,2]
C2700379
UMLS CUI [3,3]
C0012159
to minimize the likelihood of including subjects with late-onset type 1 diabetes, candidates with a positive test for anti-gad antibody or with fasting plasma c-peptide less than 0.76 ng/l (<0.25 pmol/l) were excluded
Description

Late onset Insulin-Dependent Diabetes Mellitus | Anti-GAD antibody positive | Plasma C-peptide level Fasting

Type de données

boolean

Alias
UMLS CUI [1,1]
C4025592
UMLS CUI [1,2]
C0011854
UMLS CUI [2]
C1167896
UMLS CUI [3,1]
C1303121
UMLS CUI [3,2]
C0015663
also excluded were patients with abnormal laboratory tests, including liver enzymes (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase) greater than 3 times the upper limit of normal, and serum creatinine greater than 123.8
Description

Laboratory test result abnormal | Elevated liver enzymes | Alanine aminotransferase increased | Aspartate aminotransferase increased | Alkaline phosphatase raised | Creatinine measurement, serum

Type de données

boolean

Alias
UMLS CUI [1]
C0438215
UMLS CUI [2]
C0235996
UMLS CUI [3]
C0151905
UMLS CUI [4]
C0151904
UMLS CUI [5]
C0151849
UMLS CUI [6]
C0201976
μmol/l (1.4 mg/dl).
Description

ID.8

Type de données

boolean

Retour au début de la page

Similar models

Eligibility Type 2 Diabetes NCT00815399

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age | Diabetes Mellitus, Non-Insulin-Dependent | Hypoglycemic Agents Absent | Body mass index | Hemoglobin A1c measurement
Item
men and women aged 30-75 years, with newly-diagnosed type 2 diabetes (according to the ada criteria) and never treated with antihyperglycemic drugs, were selected for the study. inclusion criteria also included a body mass index (bmi) >25 kg/m2, and hba1c level <10%.
boolean
C0001779 (UMLS CUI [1])
C0011860 (UMLS CUI [2])
C0020616 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C1305855 (UMLS CUI [4])
C0474680 (UMLS CUI [5])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
pregnancy or breast-feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Investigational New Drugs
Item
any investigational drug within the previous 3 months
boolean
C0013230 (UMLS CUI [1])
Pharmaceutical Preparations Affecting Glycaemia control | Glucocorticoids, Systemic | Weight-Loss Agents
Item
use of agents affecting glycemic control (systemic glucocorticoids, and weight-loss drugs)
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C3267174 (UMLS CUI [1,3])
C3540777 (UMLS CUI [2])
C0376606 (UMLS CUI [3])
Disease Somatic | Mental disorders | Adherence Poor Diet therapy
Item
presence of any clinically relevant somatic or mental diseases that anticipated poor adherence to diet regimens
boolean
C0012634 (UMLS CUI [1,1])
C2986476 (UMLS CUI [1,2])
C0004936 (UMLS CUI [2])
C1510802 (UMLS CUI [3,1])
C2700379 (UMLS CUI [3,2])
C0012159 (UMLS CUI [3,3])
Late onset Insulin-Dependent Diabetes Mellitus | Anti-GAD antibody positive | Plasma C-peptide level Fasting
Item
to minimize the likelihood of including subjects with late-onset type 1 diabetes, candidates with a positive test for anti-gad antibody or with fasting plasma c-peptide less than 0.76 ng/l (<0.25 pmol/l) were excluded
boolean
C4025592 (UMLS CUI [1,1])
C0011854 (UMLS CUI [1,2])
C1167896 (UMLS CUI [2])
C1303121 (UMLS CUI [3,1])
C0015663 (UMLS CUI [3,2])
Laboratory test result abnormal | Elevated liver enzymes | Alanine aminotransferase increased | Aspartate aminotransferase increased | Alkaline phosphatase raised | Creatinine measurement, serum
Item
also excluded were patients with abnormal laboratory tests, including liver enzymes (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase) greater than 3 times the upper limit of normal, and serum creatinine greater than 123.8
boolean
C0438215 (UMLS CUI [1])
C0235996 (UMLS CUI [2])
C0151905 (UMLS CUI [3])
C0151904 (UMLS CUI [4])
C0151849 (UMLS CUI [5])
C0201976 (UMLS CUI [6])
ID.8
Item
μmol/l (1.4 mg/dl).
boolean
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial